{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:15:32Z","timestamp":1788250532853,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"DOI":"10.1038\/s41531-026-01483-9","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:07:01Z","timestamp":1784286421000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Considerations on combination therapies for disease modification in Parkinson\u2019s"],"prefix":"10.1038","volume":"12","author":[{"given":"Rachel M.","family":"Hughes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Pilcicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Klee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Ducotterd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Mortiboys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon R. W.","family":"Stott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"1483_CR1","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1007\/s00415-020-10162-5","volume":"268","author":"M Smedinga","year":"2021","unstructured":"Smedinga, M., Darweesh, S., Bloem, B., Post, B. & Richard, E. Towards early disease modification of Parkinson\u2019s disease: a review of lessons learned in the Alzheimer field. J. Neurol 268, 724\u2013733 (2021).","journal-title":"J. Neurol"},{"key":"1483_CR2","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41582-024-01023-0","volume":"20","author":"L Kalia","year":"2024","unstructured":"Kalia, L. et al. Disease-modifying therapies for Parkinson disease: lessons from multiple sclerosis. Nat. Rev. Neurol 20, 724\u2013737 (2024).","journal-title":"Nat. Rev. Neurol"},{"key":"1483_CR3","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s00702-022-02520-6","volume":"129","author":"M H\u00f6llerhage","year":"2022","unstructured":"H\u00f6llerhage, M., Klietz, M. & H\u00f6glinger, G. U. Disease modification in Parkinsonism: obstacles and ways forward. J. Neural Transm. 129, 1133\u20131153 (2022).","journal-title":"J. Neural Transm."},{"key":"1483_CR4","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1200\/JCO.2011.37.6418","volume":"31","author":"TA Yap","year":"2013","unstructured":"Yap, T. A., Omlin, A. & de Bono, J. S. Development of therapeutic combinations targeting major cancer signaling pathways. J. Clin. Oncol. 31, 1592\u20131605 (2013).","journal-title":"J. Clin. Oncol."},{"key":"1483_CR5","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1182\/blood.V26.5.642.642","volume":"26","author":"E Frei","year":"1965","unstructured":"Frei, E. et al. The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood 26, 642\u2013656 (1965).","journal-title":"Blood"},{"key":"1483_CR6","doi-asserted-by":"publisher","first-page":"38022","DOI":"10.18632\/oncotarget.16723","volume":"8","author":"R Bayat Mokhtari","year":"2017","unstructured":"Bayat Mokhtari, R. et al. Combination therapy in combating cancer. Oncotarget 8, 38022\u201338043 (2017).","journal-title":"Oncotarget"},{"key":"1483_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae302","volume":"30","author":"EY Chen","year":"2025","unstructured":"Chen, E. Y. et al. Trends in complexity of single-agent and combination therapies for solid tumor cancers approved by the US Food and Drug Administration. Oncologist 30, oyae302 (2025).","journal-title":"Oncologist"},{"key":"1483_CR8","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41579-018-0141-x","volume":"17","author":"M Tyers","year":"2019","unstructured":"Tyers, M. & Wright, G. D. Drug combinations: a strategy to extend the life of antibiotics in the 21st century. Nat. Rev. Microbiol. 17, 141\u2013155 (2019).","journal-title":"Nat. Rev. Microbiol."},{"key":"1483_CR9","first-page":"1756","volume":"44","author":"K Kieburtz","year":"1994","unstructured":"Kieburtz, K. et al. The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson\u2019s disease. Parkinson Study Group. Neurol. 44, 1756\u20131759 (1994).","journal-title":"Parkinson Study Group. Neurol."},{"key":"1483_CR10","doi-asserted-by":"publisher","first-page":"e001070","DOI":"10.1136\/bmjno-2025-001070","volume":"7","author":"SJ Lewis","year":"2025","unstructured":"Lewis, S. J., Sue, C. M., Cooper, A. & Halliday, G. M. Future is now: an Australasian perspective on disease-modifying trials in Parkinson\u2019s and prodromal disease. BMJ Neurol. Open 7, e001070 (2025).","journal-title":"BMJ Neurol. Open"},{"key":"1483_CR11","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1002\/ana.78190","volume":"99","author":"A Shtilbans","year":"2026","unstructured":"Shtilbans, A. & Lang, A. E. Combination disease-modifying therapy for neurodegenerative diseases using repurposed drugs. Ann. Neurol. 99, 1099\u20131112 (2026).","journal-title":"Ann. Neurol."},{"key":"1483_CR12","doi-asserted-by":"publisher","first-page":"fcae478","DOI":"10.1093\/braincomms\/fcae478","volume":"7","author":"B Yulug","year":"2025","unstructured":"Yulug, B. et al. Multi-omics characterization of improved cognitive functions in Parkinson\u2019s disease patients after the combined metabolic activator treatment: a randomized, double-blinded, placebo-controlled phase II trial. Brain Commun. 7, fcae478 (2025).","journal-title":"Brain Commun."},{"key":"1483_CR13","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1007\/s10787-025-01752-8","volume":"33","author":"ME Ramadan","year":"2025","unstructured":"Ramadan, M. E., Mostafa, T. M., Ghali, A. A. & El-Afify, D. R. Randomized controlled trial evaluating synbiotic supplementation as an adjuvant therapy in the treatment of Parkinson\u2019s disease. Inflammopharmacology 33, 3897\u20133908 (2025).","journal-title":"Inflammopharmacology"},{"key":"1483_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/mds.26120","volume":"30","author":"A Lees","year":"2015","unstructured":"Lees, A., Tolosa, E. & Olanow, C. W. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr. Mov. Disord. Off. J. Mov. Disord. 30, 19\u201336 (2015).","journal-title":"Mov. Disord. Off. J. Mov. Disord."},{"key":"1483_CR15","doi-asserted-by":"crossref","unstructured":"TREATMENT of pulmonary tuberculosis with streptomycin and para-aminosalicylic acid; a Medical Research Council investigation. Br. Med. J. 2, 1073\u20131085 (1950).","DOI":"10.1136\/bmj.2.4688.1073"},{"key":"1483_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nrd1609","volume":"4","author":"CT Keith","year":"2005","unstructured":"Keith, C. T., Borisy, A. A. & Stockwell, B. R. Multicomponent therapeutics for networked systems. Nat. Rev. Drug Discov. 4, 71\u201378 (2005).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1483_CR17","doi-asserted-by":"publisher","unstructured":"Fernandez, P. et al. Rethinking our strategies to develop disease-modifying therapies for Parkinson\u2019s: Time for combination therapies? J. Park. Dis. 1877718X261434686 https:\/\/doi.org\/10.1177\/1877718X261434686 (2026).","DOI":"10.1177\/1877718X261434686"},{"key":"1483_CR18","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"D Athauda","year":"2017","unstructured":"Athauda, D. et al. Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Lond. Engl. 390, 1664\u20131675 (2017).","journal-title":"Lancet Lond. Engl."},{"key":"1483_CR19","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","volume":"405","author":"N Vijiaratnam","year":"2025","unstructured":"Vijiaratnam, N. et al. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson\u2019s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. Lancet Lond. Engl. 405, 627\u2013636 (2025).","journal-title":"Lancet Lond. Engl."},{"key":"1483_CR20","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3390\/molecules29030585","volume":"29","author":"BG de la Torre","year":"2024","unstructured":"de la Torre, B. G. & Albericio, F. The Pharmaceutical Industry in 2023: An Analysis of FDA Drug Approvals from the Perspective of Molecules. Molecules. 29, 585 (2024).","journal-title":"Molecules."},{"key":"1483_CR21","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.mehy.2011.02.003","volume":"76","author":"EC Lauterbach","year":"2011","unstructured":"Lauterbach, E. C. Dextromethorphan as a potential rapid-acting antidepressant. Med. Hypotheses 76, 717\u2013719 (2011).","journal-title":"Med. Hypotheses"},{"key":"1483_CR22","doi-asserted-by":"publisher","first-page":"609","DOI":"10.9758\/cpn.23.1081","volume":"21","author":"B McCarthy","year":"2023","unstructured":"McCarthy, B. et al. Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder. Clin. Psychopharmacol. Neurosci. Sci. J. Korean Coll. Neuropsychopharmacol. 21, 609\u2013616 (2023).","journal-title":"Clin. Psychopharmacol. Neurosci. Sci. J. Korean Coll. Neuropsychopharmacol."},{"key":"1483_CR23","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/01.jcp.0000162805.46453.e3","volume":"25","author":"M Kotlyar","year":"2005","unstructured":"Kotlyar, M. et al. Inhibition of CYP2D6 activity by bupropion. J. Clin. Psychopharmacol. 25, 226\u2013229 (2005).","journal-title":"J. Clin. Psychopharmacol."},{"key":"1483_CR24","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1176\/appi.ajp.21080800","volume":"179","author":"H Tabuteau","year":"2022","unstructured":"Tabuteau, H., Jones, A., Anderson, A., Jacobson, M. & Iosifescu, D. V. Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial. Am. J. Psychiatry 179, 490\u2013499 (2022).","journal-title":"Am. J. Psychiatry"},{"key":"1483_CR25","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1111\/j.1471-4159.2006.03782.x","volume":"97","author":"K Kubota","year":"2006","unstructured":"Kubota, K. et al. Suppressive effects of 4-phenylbutyrate on the aggregation of Pael receptors and endoplasmic reticulum stress. J. Neurochem. 97, 1259\u20131268 (2006).","journal-title":"J. Neurochem."},{"key":"1483_CR26","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40035-022-00307-z","volume":"11","author":"K Khalaf","year":"2022","unstructured":"Khalaf, K., Tornese, P., Cocco, A. & Albanese, A. Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases. Transl. Neurodegener. 11, 33 (2022).","journal-title":"Transl. Neurodegener."},{"key":"1483_CR27","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/acn3.51648","volume":"9","author":"JA Fels","year":"2022","unstructured":"Fels, J. A., Dash, J., Leslie, K., Manfredi, G. & Kawamata, H. Effects of PB-TURSO on the transcriptional and metabolic landscape of sporadic ALS fibroblasts. Ann. Clin. Transl. Neurol. 9, 1551\u20131564 (2022).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1483_CR28","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.3390\/ijms26083865","volume":"26","author":"L Zhang","year":"2025","unstructured":"Zhang, L. et al. AMX0035 Mitigates Oligodendrocyte Apoptosis and Ameliorates Demyelination in MCAO Rats by inhibiting endoplasmic reticulum stress and mitochondrial dysfunction. Int. J. Mol. Sci. 26, 3865 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"1483_CR29","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3390\/antiox14040396","volume":"14","author":"A Shtilbans","year":"2025","unstructured":"Shtilbans, A. et al. Evaluation of additive neuroprotective effect of combination therapy for Parkinson\u2019s disease using in vitro models. Antioxidants 14, 396 (2025).","journal-title":"Antioxidants"},{"key":"1483_CR30","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1056\/NEJMoa1916945","volume":"383","author":"S Paganoni","year":"2020","unstructured":"Paganoni, S. et al. Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 383, 919\u2013930 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1483_CR31","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40261-024-01371-1","volume":"44","author":"A Ketabforoush","year":"2024","unstructured":"Ketabforoush, A. et al. Sodium Phenylbutyrate and Tauroursodeoxycholic Acid: a story of hope turned to disappointment in amyotrophic lateral sclerosis treatment. Clin. Drug Investig. 44, 495\u2013512 (2024).","journal-title":"Clin. Drug Investig."},{"key":"1483_CR32","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1158\/1078-0432.CCR-14-0521","volume":"20","author":"CJ Paller","year":"2014","unstructured":"Paller, C. J. et al. Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clin. Cancer Res. 20, 4210\u20134217 (2014).","journal-title":"Clin. Cancer Res."},{"key":"1483_CR33","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1002\/mds.29899","volume":"39","author":"M Fabbri","year":"2024","unstructured":"Fabbri, M. et al. Advantages and challenges of platform trials for disease modifying therapies in Parkinson\u2019s Disease. Mov. Disord. 39, 1468\u20131477 (2024).","journal-title":"Mov. Disord."},{"key":"1483_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103582","volume":"89","author":"V Solitano","year":"2025","unstructured":"Solitano, V. et al. An international consensus on the design of clinical trials for advanced combination treatment (ACT) in inflammatory bowel disease. EClinicalMedicine 89, 103582 (2025).","journal-title":"EClinicalMedicine"},{"key":"1483_CR35","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3390\/biomedicines10020270","volume":"10","author":"MC Michel","year":"2022","unstructured":"Michel, M. C. & Staskin, D. Study designs for evaluation of combination treatment: focus on individual patient benefit. Biomedicines 10, 270 (2022).","journal-title":"Biomedicines"},{"key":"1483_CR36","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1093\/jnci\/djad052","volume":"115","author":"E Sharon","year":"2023","unstructured":"Sharon, E. & Foster, J. C. Design of phase II oncology trials evaluating combinations of experimental agents. J. Natl. Cancer Inst. 115, 613\u2013618 (2023).","journal-title":"J. Natl. Cancer Inst."},{"key":"1483_CR37","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s11538-025-01508-z","volume":"87","author":"SF Martina-Perez","year":"2025","unstructured":"Martina-Perez, S. F. et al. Optimal control in combination therapy for heterogeneous cell populations with drug synergies. Bull. Math. Biol. 87, 159 (2025).","journal-title":"Bull. Math. Biol."},{"key":"1483_CR38","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3390\/ijms27010413","volume":"27","author":"S Jena","year":"2025","unstructured":"Jena, S. et al. Novel mixed cancer-cell models designed to capture inter-patient tumor heterogeneity for accurate evaluation of drug combinations. Int. J. Mol. Sci. 27, 413 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"1483_CR39","doi-asserted-by":"publisher","first-page":"1209416","DOI":"10.3389\/fgene.2023.1209416","volume":"14","author":"V Latapiat","year":"2023","unstructured":"Latapiat, V., Saez, M., Pedroso, I. & Martin, A. J. M. Unraveling patient heterogeneity in complex diseases through individualized co-expression networks: a perspective. Front. Genet. 14, 1209416 (2023).","journal-title":"Front. Genet."},{"key":"1483_CR40","doi-asserted-by":"publisher","first-page":"108419","DOI":"10.1016\/j.pharmthera.2023.108419","volume":"246","author":"E Menozzi","year":"2023","unstructured":"Menozzi, E., Toffoli, M. & Schapira, A. H. V. Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues. Pharmacol. Ther. 246, 108419 (2023).","journal-title":"Pharmacol. Ther."},{"key":"1483_CR41","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","volume":"23","author":"GU H\u00f6glinger","year":"2024","unstructured":"H\u00f6glinger, G. U. et al. A biological classification of Parkinson\u2019s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol. 23, 191\u2013204 (2024).","journal-title":"Lancet Neurol."},{"key":"1483_CR42","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","volume":"23","author":"T Simuni","year":"2024","unstructured":"Simuni, T. et al. A biological definition of neuronal \u03b1-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 23, 178\u2013190 (2024).","journal-title":"Lancet Neurol."},{"key":"1483_CR43","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40035-024-00421-0","volume":"13","author":"E Appleton","year":"2024","unstructured":"Appleton, E. et al. DOPA-decarboxylase is elevated in CSF, but not plasma, in prodromal and de novo Parkinson\u2019s disease. Transl. Neurodegener. 13, 31 (2024).","journal-title":"Transl. Neurodegener."},{"key":"1483_CR44","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1038\/s43587-023-00478-y","volume":"3","author":"JB Pereira","year":"2023","unstructured":"Pereira, J. B. et al. DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease. Nat. Aging 3, 1201\u20131209 (2023).","journal-title":"Nat. Aging"},{"key":"1483_CR45","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s00401-024-02706-0","volume":"147","author":"J Rutledge","year":"2024","unstructured":"Rutledge, J. et al. Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson\u2019s disease. Acta Neuropathol. 147, 52 (2024).","journal-title":"Acta Neuropathol."},{"key":"1483_CR46","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/mds.70102","volume":"41","author":"M Camacho","year":"2026","unstructured":"Camacho, M. et al. Constipation Is Linked to Neuroinflammation in Early Parkinson\u2019s Disease. Mov. Disord. 41, 455\u2013465 (2026).","journal-title":"Mov. Disord."},{"key":"1483_CR47","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/brain\/awad322","volume":"147","author":"A Kouli","year":"2024","unstructured":"Kouli, A. et al. Neuroinflammation is linked to dementia risk in Parkinson\u2019s disease. Brain J. Neurol. 147, 923\u2013935 (2024).","journal-title":"Brain J. Neurol."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01483-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01483-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01483-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T13:01:55Z","timestamp":1784293315000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-026-01483-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1483"],"URL":"https:\/\/doi.org\/10.1038\/s41531-026-01483-9","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"17 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RH, AP, SS declare non-financial competing interests as employees of Cure Parkinson\u2019s. TK \u2013 This author does not have a competing interest. FD \u2013 This author declares a non-financial competing interest as they are a member of Parkinson\u2019s UK Research Ventures Board. HM \u2013 This author declares a non-financial competing interest as the co-founder and CEO of Mitotype Precision Labs.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"173"}}